HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 26, Nos. 05 & 06, May & June 2022 – Living Better for Longer: Cutting-Edge Research in Geriatric Medicine       » How Oxidation Can Lead to Mitochondrial Dysfunction and Age-Dependent Cognitive Disorders       » New Semiconductor Microchip Detects Prostate Cancer Markers With Ultra-High Sensitivity       » New Method for Synthesising Sulphur-Based Medicines Can Boost Drug Discovery Efficiency and Speed       » Selecting the Best Target for Deep Brain Stimulation in Parkinson’s Disease       » A Single Metabolite Can Promote Tissue Regeneration and Delay Ageing       » A New Light-Sensitive Way to Control Parathyroid Hormone Secretion for the Prevention of Bone Loss      
NEWS CRUNCH
BioSingapore Launches White Paper on the Future of BioSciences in Singapore
'The Next Lap - Biosciences in Singapore 2025'

SINGAPORE - The next 10 years of Singapore's biosciences industry is the focus of a new white paper that captures the views and predictions of the nation's biosciences industry leaders.

"The Next Lap - Biosciences in Singapore 2025" was produced in conjunction with Clearstate, an Economist Intelligence Unit business. It summarizes the development of Singapore's biosciences cluster to date and compares it with successful bioscience clusters in Israel, Taiwan and South Korea. The white paper provides insights on research and development and commercialisation opportunities, and highlights the talent needed to help Singapore sustain and entrench its position as the "Biopolis of Asia".

Simranjit Singh, Executive Council BioSingapore, said that over the past 15 years, Singapore has succeeded in building a reputation as a regional powerhouse in biosciences, but challenges such as limited resources and rising costs persist. He said there is a need for Singapore to increase its focus on key areas of research where it has a distinctive advantage.

Singh said: "The next phase of development presents new challenges & opportunities for Singapore as healthcare markets undergo transformational shifts on a global scale. As we look ahead to 2025, the bioscience sector should consider how best to create success stories that inspire more biosciences companies to establish & grow in Singapore."

Commercialisation remains at an early stage with big gaps in venture funding and management experience in bringing healthcare products to the market, he said. There are also opportunities untapped in emerging markets in Asia that could be a robust growth engine as demand for healthcare services in these markets is predicated to soar, Singh said.

About BioSingapore

BioSingapore, started by the Singapore Economic Development Board in 2004, is a leading life sciences association serving Singapore and the ASEAN region. Our vision is to enable a successful and vibrant life sciences community by connecting the industry to solutions.

Source: Quintiles
NEWS CRUNCH  
news Medtec China 2022 Is Now Open for Visitor Registration, Helping Medical Device Manufacturers in Medtech Sourcing and Supply Chain Stabilisation
news Inaugural Asia Summit on Global Health highlights Hong Kong's advantages
news Asia Summit on Global Health (ASGH) 2021 — Shaping a Resilient and Sustainable Future
news TechInnovation 2021 Virtual Exhibition to Showcase Sustainable Energy, Food, and Healthcare Solutions
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   [email protected] or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   [email protected]
Copyright© 2022 World Scientific Publishing Co Pte Ltd  •  Privacy Policy